Galectin Therapeutics receives FDA alignment on belapectin trial design; secures $10M credit line

GALECTIN THERAPEUTICS INC

FDA written response on belapectin shows alignment on patient population for registration trial; follow-up Type C meeting planned.
Follow-up meeting to finalize trial design and present biomarker data from AASLD meeting not included in prior submission.
Entered $10M unsecured, convertible line of credit from chairman Richard E. Uihlein; maturity extended to June 30, 2027.
Existing credit facilities also extended; company expects funding through at least March 2027.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

GALECTIN THERAPEUTICS INC entered into December 2025 Supplemental Line of Credit Agreement with Richard E. Uihlein valued at up to $10.00 million line of credit (effective 2025-12-19).

Action: entry
Agreement: credit facility
Counterparty: Richard E. Uihlein
Value: up to $10.00 million line of credit
Effective: 2025-12-19

Exact text from the filing

On December 19, 2025, Galectin Therapeutics Inc. (the “Company”) and Richard E. Uihlein (the “Lender”) entered into a Line of Credit Letter Agreement (the “December 2025 Supplemental Line of Credit Agreement”), pursuant to which the Lender shall provide the Company a line of credit of up to $10.00 million (the “Line of Credit”) to finance the Company’s working capital needs.

View on SEC.gov

Browse all material agreements →

GALECTIN THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001140361-25-046115

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.